Final HIV status outcome for HIV-exposed infants at 18 months of age in nine states and the Federal Capital Territory, Nigeria

Babatunde Adelekan1*, Bidemi Harry-Erin1‡, Martha Okposo1, Ahmad Aliyu1, Nicaise Ndembali2,3, Patrick Dakum3,4, Nadia A. Sam-Agudu3,4,5

1 Strategic Information, Institute of Human Virology Nigeria, Abuja, Nigeria, 2 Laboratory Research, Institute of Human Virology Nigeria, Abuja, Nigeria, 3 Department of Pediatrics, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, United States of America, 4 Prevention, Care and Treatment Unit, Institute of Human Virology Nigeria, Abuja, Nigeria, 5 International Research Center of Excellence, Institute of Human Virology Nigeria, Abuja, Nigeria

* tundeadelekan1@gmail.com

Abstract

Introduction

While antiretroviral therapy (ART) coverage for pregnant women has undergone steady scale-up, Nigeria’s final mother-to-child transmission of HIV (MTCT) rate remains unacceptably high at 10%. This study aimed to determine final outcomes (MTCT rates) and their correlates among HIV-exposed infants (HEI) in nine states and the Federal Capital Territory, Nigeria.

Methods

This retrospective, cross-sectional study was conducted at 96 primary, secondary and tertiary health facilities supported by the Institute of Human Virology Nigeria. Data was abstracted for a birth cohort of HEI born between October 30, 2014 and April 30, 2015 whose 18–24 month final outcome was assessed by October 30, 2016. Only infants with a six-week first DNA PCR result, and a rapid HIV antibody test result at age 18 to 24 months were included. Multivariate logistic regression (adjusted odds ratios [aORs]) evaluated for predictors of HIV positivity at ≥18 months.

Results

After testing at ≥18 months, 68 (2.8%) of the 2,405 exposed infants in the birth cohort were HIV-positive. After a minimum of 18 months of follow-up, 51 (75%) HIV-positive infants were alive on ART; 7 (10%) had died, 5 (7.3%) were lost to follow-up and 5 (7.3%) were transferred out. Rural maternal residence, lack of maternal ART/ARV prophylaxis, mixed infant feeding and infant birth weight less than 2.5 kg correlated with an HIV-positive status for infant final outcomes.
Conclusion

The final HIV positivity rate of 2.8% is encouraging, but is not population-based. Nevertheless, supported by our findings, we recommend continued programmatic focus on early access to quality prenatal care and maternal ART for pregnant women, especially for women living with HIV in rural areas. Furthermore, implementation of nationwide sensitization and education on six-months’ exclusive infant breastfeeding with concurrent maternal ART should be strengthened and sustained to reduce MTCT rates.

Introduction

Nigeria has the third-largest HIV burden in the world, after Mozambique and South Africa. In 2020, there were an estimated 21,000 new child HIV infections in Nigeria, the highest in the world [1], which accounted for 14% of the global estimate [2]. Furthermore, at 15% and 10% respectively, Nigeria had the second-highest six-week and breastfeeding mother-to-child transmission of HIV (MTCT) rate in 2020 [1]. The UNAIDS has targeted final transmission rates of <2% and <5% among non-breastfeeding and breastfeeding infants, respectively for the elimination of mother-to-child transmission of HIV [3]. To reduce these high MTCT rates and new child HIV infections, uptake of, and compliance with interventional services in the prevention of mother-to-child transmission of HIV (PMTCT) cascade are critically important. The PMTCT cascade is a comprehensive multistep continuum of care to be completed by HIV-positive mother-exposed infant pairs, and includes maternal antenatal HIV testing and treatment, antenatal and delivery care, early infant diagnosis, postnatal services and linkage to long-term HIV care and support, which includes final HIV outcome testing for the HEI at 18 months of age [4].

From its inception to date, the national PMTCT program has been coordinated by the Federal Government of Nigeria and implemented largely at the subnational level by states, with substantial donor contributions such as from the US President’s Emergency Plan for AIDS Relief (PEPFAR). Federally-issued national guidelines drive PMTCT service implementation in line with scientific developments and international best practices based on World Health Organization (WHO) recommendations, with the overall goal to improve maternal health and child survival through accelerated provision of comprehensive and integrated PMTCT services. The Nigerian PMTCT program started in tertiary institutions in 2002 and was later decentralized to secondary hospitals and primary healthcare centers in both public and private settings. Technical, financial and logistic support is provided to PMTCT programs at both public and private facilities by donors and partners, including PEPFAR and its non-governmental organization implementing partners [5].

Along with reporting encouraging strides in the global elimination of MTCT agenda, *The Global Plan towards the Elimination of New HIV Infections among Children by 2015 and Keeping Their Mothers Alive* [6] highlighted Nigeria’s wide PMTCT cascade performance gaps. This included low maternal antiretroviral therapy (ART) coverage (30%) and poor early infant diagnosis testing rates (11%), coupled with high rates of early and late MTCT. Ultimately, only 21% of HIV-infected Nigerian children received ART at the end of the Global Plan’s 2011 to 2015 assessment period [3]. Additionally, a 2008 to 2014 audit from the Nigerian national HIV program reported only limited improvements in antenatal maternal HIV testing, with up to 42% of HIV-positive women at PMTCT facilities not receiving ART [7]. The audit also
reported maternal ART coverage at only 30% in 2014 [7], however it did not provide PMTCT cascade information on any infant nor maternal outcomes beyond antenatal ART coverage. More recently, in 2020, only 32% of pregnant women in Nigeria received HIV testing, and 44% accessed maternal ART [1]. Also, only 27% of HIV-exposed infants (HEI) received a virological test for HIV within 2 months of birth [8], with a cumulative final MTCT rate of 25% in this group [1, 8].

There is published data on the early part of the PMTCT cascade in Nigeria, largely antenatal maternal outcomes through early infant diagnosis at 2 months [7–13]. However, there is little available data on the latter part of the cascade, particularly on final HIV status outcomes for HEI at or after 18 months of age [14, 15]. Besides generating more data on HEI final outcomes, it is important to understand the factors that potentiate or prevent HIV-infection in this population. This study aimed to determine final outcomes (MTCT rates) and their correlates among HIV-exposed infants in nine states and the Federal Capital Territory in Nigeria, a country critical to achieving the global goal for elimination of mother-to-child transmission of HIV.

Methods

Study setting

This retrospective cross-sectional study focused on HEI seen at public and private healthcare facilities across nine states and the Federal Capital Territory in Nigeria, namely, Benue, Delta, Ekiti, Kano, Katsina, Nasarawa, Ogun, Ondo and Osun. HIV services at healthcare facilities in these states were supported by the Institute of Human Virology Nigeria (IHVN) with PEPFAR funding. IHVN is a large local non-governmental organization that provides public health services including for malaria, tuberculosis, and HIV, to healthcare facilities in Nigeria [16].

The primary, secondary and tertiary facilities supported by IHVN and included in the analysis were located across the spectrum of rural and urban settings, with primary facilities located largely in rural areas, secondary facilities in both rural and urban areas, and tertiary facilities concentrated in urban areas. Additionally, tertiary facilities also serve as referral centers at which patients from within and outside the state access higher-level care.

Study population and data collection

We reviewed available records of infants born between October 30, 2014 and April 30, 2015 who had final outcome results available by October 30, 2016. This birth cohort attained 18 to 24 months of age by October 30, 2016. We prioritized data analysis for this birth cohort of HEI because 2014 was the first year of implementation for a newly-implemented longitudinal birth cohort register that linked the mother-infant pair in the PMTCT program. HIV positive final outcome refers to the status of HEIs identified as HIV-infected after testing positive for HIV antibodies at ≥18 months of age and/or 6 weeks after cessation of breastfeeding [17].

In 2014/2015, national guidelines recommended that all HEI were to be tested for HIV by DNA PCR using dried blood samples, for early infant diagnosis (EID) between 6 weeks and 2 months of age, and at 6 weeks after breastfeeding [17]. Infants older than 9 months could first be screened with rapid antibody testing, and if positive, undergo PCR testing for confirmation [17]. There was no birth testing nor mandatory repeat PCR testing recommendation after first DNA PCR for HEI in 2014/2015 [17]. HEI testing negative at first DNA PCR were tested for final outcome by rapid antibody testing between 18 and 24 months of age [17, 18]. The delay period of final outcome testing to up to 24 months is to reduce the possibility of false positives from maternal antibodies which may occur in younger children.
Only HEI with an available DNA PCR result at ≤6 weeks of birth and an HIV rapid test result at ≥18 months of age were eligible for inclusion. All HEI who had a positive DNA PCR test collected between 6 weeks and less than 18 months of age were excluded from final outcome analysis. In addition to HEI HIV test data, socio-demographic and clinical parameters were collected on infants and their HIV-positive mothers. Site-level data clerks de-identified data from IHVN’s electronic HIV program database and from hard-copy program registers at supported facilities in the nine states and the Federal Capital Territory. State-level Monitoring and Evaluation program officers collated site data and submitted it to the Central Strategic Information Unit in secured, encrypted Excel files for analysis.

**Statistical analysis**

After abstraction and cleaning, relevant data from mother-infant pairs meeting the eligibility criteria were migrated into Stata 14 (StataCorp. 2015. *Stata Statistical Software: Release 14*. College Station, TX: StataCorp LP). Descriptive analysis was performed, after which bi-variate analysis using Chi-square, Fisher’s exact and likelihood ratios were conducted to test for associations between HEI final outcomes and maternal-infant characteristics. Explanatory variables significant at p < 0.05 from bi-variate analysis were inputted into a model for multivariate logistic regression to establish predictors of HIV infant positivity at 18–24 months of age. The binary dependent variable was HEI who were positive or negative after HIV rapid testing at ≥18 months. Independent variables were divided into two main domains: maternal data including age and marital, education and employment status at antenatal care clinic booking, facility type attended, place of delivery, and receipt of ART; and infant data including gender, birth weight, DNA PCR result, and infant feeding practice.

**Ethical approval**

The study was approved by the Nigerian National Health Research Ethics Committee (NHREC/01/01/2007-01/03/2021D) for secondary analysis of routine data collected by the Institute of Human Virology Nigeria’s HIV program. The data reviewed and presented in this study were collected as part of routine HIV program activities.

**Results**

Data were collected from 96 IHVN-supported healthcare facilities (19 private, 77 public) across nine states and the Federal Capital Territory in Nigeria. Data from 2,405 HEI and their HIV-infected mothers were included in our analysis (Table 1). Of the 96 study facilities, 55 (57.3%) were primary-level, 28 (29.2%) secondary and 13 (13.5%) tertiary. Approximately 50% of the mother-infant pairs in our cohort received PMTCT services at tertiary-level facilities.

| Facility Level Type | Number of HEI (n (%)) |
|---------------------|-----------------------|
| Primary: 55 (57.3)  | 481 (20.0)            |
| Secondary: 28 (29.2)| 721 (30.0)            |
| Tertiary: 13 (13.5) | 1,203 (50.0)          |
| **Total: 96**       | **Total: 2,405**      |

https://doi.org/10.1371/journal.pone.0263921.t001
Socio-demographic and clinical characteristics of mother-infant pairs

Approximately 94% of the pregnant women living with HIV in this analysis were married, 63% had at least a primary education while 56% were employed. Almost all (97%) of the women in this cohort delivered at a health facility and via spontaneous vaginal delivery. Our study population of HEI comprised 52.7% (1,257) males (Table 2) and had a mean (±SD) birth weight of 2.96 (±0.465) kg.

Final HIV status and clinical assessment among HIV-exposed infants

Out of the 2,405 HEI, 68 (2.8%) had an HIV-positive final outcome status. Of these, 8 (11.8%) initially tested HIV-negative, and then converted to HIV-positive for final outcome, while 6 (9%) of previously DNA PCR positive HEI tested negative at final outcome (Fig 1). Out of the 68 HEI with HIV positive final outcome, 75% (n = 51) were alive and on anti-retroviral therapy, 10.3% (n = 7) had died, 5.9% (n = 4) were lost to follow-up and 8.8% (n = 6) were transferred out by age 24 months. Furthermore, among HEI with HIV-negative final outcome, 2,335 (99.9%) were discharged to routine pediatric care, 1 (0.04%) was lost to follow-up and 1 (0.04) was transferred out to another facility (Table 2). Clinical assessment also showed that of the 2,405 infants, 51 (2.1%) were alive and on ART, 2,335 (97.1%) were discharged to routine pediatric care, 7 (0.3%) were transferred out to other facility, 7 (0.3%) died and 5 (0.2) were lost to follow-up (Fig 1).

Relationship between maternal factors and final HIV status of HIV-exposed infants

In bivariate regression analysis, maternal marital status of “married” was associated with infants’ HIV-positive final outcome (3% married vs 0% not married, p = 0.032) (Table 2). Maternal educational level was also significantly associated with HIV-positive final outcomes among HEI, with the proportion positive decreasing as the level of maternal education increased, from 3.1% among women with primary education to 1.8% among those with secondary or post-secondary education (p = 0.007). Interestingly, there were no HIV-positive infants among women with no education in our cohort. Furthermore, maternal unemployment (p = 0.042), rural residence (p = 0.002), CD4 >500 copies/ml (p = 0.004), and non-receipt of ART (p<0.001) were also associated with HIV-positive final outcome among HEI (Table 2).

Relationship between infant factors and final HIV status of HIV-exposed infants

Bivariate analysis revealed that compared to those whose mothers received PMTCT drug interventions (2.5%), a higher proportion of infants with unknown (35.3%) or no (13.3%) maternal PMTCT intervention were ultimately HIV-positive (p<0.001, Table 2). Infant birthweight <2.5 kg, maternal-reported mixed feeding methods, and as expected, positive DNA PCR at or before 6 weeks of life also correlated with final HIV positive status.

Predictors of HIV positive final outcomes among HIV-exposed infants

Multivariate logistic regression analysis determined characteristics associated with lower odds of HIV-positive final outcomes as maternal urban residence (OR 0.47, p = 0.006) and exclusive breastfeeding (OR 0.52, p<0.001). Maternal delivery outside health facilities (OR 2.20, p = 0.025), non-receipt of maternal ART (OR 4.76, p = 0.024), or of infant PMTCT
Table 2. Socio-demographic and clinical characteristics of mother-infant pairs.

| Maternal\textsuperscript{1}-Infant characteristics | Final HIV Status Outcome | \( ^\star\) HIV positive (N = 68) n (%) | \( ^\star\) HIV negative (N = 2,337) n (%) | \( \star\star\) Total HEI (N = 2405) n (%) | P value |
|-----------------------------------------------|-------------------------|--------------------------------------|--------------------------------------|--------------------------------------|--------|
| Marital status \( ^a \) | | 68 (3.0) | 2,195 (97.0) | 2,263 (94.1) | 0.032\( ^g \) |
| Married | 68 (3.0) | 2,195 (97.0) | 2,263 (94.1) | | |
| Not Married \( ^b \) | 0 (0.0) | 142 (100.0) | 142 (5.9) | | |
| Maternal Level of Education \( ^c \) | | | | | |
| No education | 0 (0.0) | 59 (100.0) | 59 (2.5) | | 0.007\( ^g \) |
| Primary | 15 (3.1) | 463 (96.9) | 478 (19.9) | | |
| Secondary/Post-Secondary | 19 (1.8) | 1,020 (99.2) | 1,039 (43.2) | | |
| Unknown | 34 (4.1) | 795 (95.9) | 829 (34.5) | | |
| Maternal Occupation \( ^d \) | | | | | |
| Working | 46 (3.4) | 1,290 (96.6) | 1,336 (55.6) | | 0.042 |
| Not working | 22 (2.1) | 1,047 (97.9) | 1,069 (44.6) | | |
| Maternal Residence \( ^e \) | | | | | |
| Rural | 23 (4.3) | 516 (95.7) | 539 (22.4) | | 0.002\( ^d \) |
| Urban | 35 (2.1) | 1,666 (97.2) | 1,701 (70.7) | | |
| Unknown | 10 (6.1) | 155 (93.9) | 165 (6.5) | | |
| Maternal Age (Years) \( ^f \) | | | | | |
| <25 | 9 (3.07) | 284 (96.9) | 293 (12.2) | | 0.727\( ^d \) |
| 25–49 | 59 (2.8) | 2,043 (97.2) | 2,102 (87.4) | | |
| 50+ | 0 (0.0) | 10 (100.0) | 10 (0.4) | | |
| Maternal place of delivery \( ^g \) | | | | | |
| Health Facility | 57 (2.6) | 2,107 (97.4) | 2,164 (90.0) | | 0.097 |
| Non-health facility | 10 (5.6) | 173 (94.4) | 178 (7.4) | | |
| Unknown | 1 (1.6) | 62 (98.4) | 63 (2.6) | | |
| Maternal Mode of delivery \( ^h \) | | | | | |
| Spontaneous Vaginal | 66 (2.9) | 2,178 (97.1) | 2,244 (93.3) | | 0.321\( ^g \) |
| Caesarean section | 2 (1.2) | 159 (98.8) | 161 (6.7) | | |
| Maternal ANC CD4\( ^i \) | | | | | |
| <500 | 7 (1.3) | 526 (98.7) | 533 (22.2) | | 0.004 |
| 500+ | 6 (1.5) | 389 (98.5) | 395 (16.4) | | |
| Unknown | 55 (3.7) | 1,422 (96.3) | 1,477 (61.4) | | |
| Maternal ART/ARV Prophylaxis \( ^d \) | | | | | |
| Yes | 45 (2.0) | 2,157 (98.0) | 2,202 (91.6) | | <0.001 |
| No | 4 (16.7) | 20 (83.3) | 24 (1.0) | | |
| Unknown | 19 (10.6) | 160 (89.4) | 179 (7.4) | | |
| Infant Characteristics and Information | | | | | |
| Infant Weight (Kg) | | | | | |
| <2.5 | 13 (5.1) | 240 (94.9) | 252 (10.5) | | 0.019 |
| 2.5+ | 55 (2.6) | 2,097 (97.4) | 2,152 (89.5) | | |
| Infant sex | | | | | |
| Male | 35 (2.8) | 1,232 (97.2) | 1,267 (52.7) | | 0.839 |
| Female | 33 (2.9) | 1,105 (97.1) | 1,138 (47.3) | | |
| Infant DNA PCR result \( ^c \) | | | | | |
| Positive | 60 (90.9) | 6 (9.1) | 66 (2.7) | | <0.001 |
| Negative | 8 (0.3) | 2,325 (99.7) | 2,333 (97.0) | | |

(Continued)
interventions (OR 4.57, \( p = 0.021 \)) and infant birthweight < 2.5kg (OR 0.48, \( p = 0.022 \)) were associated with higher odds of HIV-positive final outcomes for HEI (Table 3).

The full model containing all predictors was statistically significant \( \chi^2 (12) = 105.52, p < 0.001 \), indicating ability to differentiate HEI with positive or negative outcomes at \( \geq 18 \) months. The model explained 17% (Pseudo \( R^2 = 0.1721 \)) of the variability in HEI outcomes and correctly classified 76.5% of the cases. HEI with birthweight of \( \geq 2.5 \) kg had 60% (aOR 0.40, \( p = 0.009 \)) reduced risk of being HIV-positive compared to those with low birthweight of <2.5 kg. Pregnant women living with HIV in urban areas had a 55% (aOR 0.45, \( p = 0.008 \)) decreased likelihood of having an infant with final HIV positive status compared to those living in rural areas. HEI who were reported as exclusively breastfed for six months had a 96% reduced likelihood of vertical transmission (aOR 0.04, \( p < 0.001 \)) compared to those receiving

### Table 2. (Continued)

| Final HIV Status Outcome | **Total HEI (N = 2405)** |
|--------------------------|--------------------------|
| `HIV positive (N = 68)` n (%) | `HIV negative (N = 2,337)` n (%) | \( \chi^2 \) (12) = 105.52, \( p < 0.001 \) |
| Unknown | 0 (0.0) | 6 (100.0) | 6 (0.3) |
| Infant feeding practice | | | |
| Mixed | 12 (27.9) | 31 (72.1) | 43 (1.8) | \( <0.001 \)^f |
| Exclusive Breastfeeding | 51 (2.3) | 2,126 (97.7) | 2,177 (90.5) |
| Exclusive Replacement | 0 (0.0) | 100 (100.0) | 100 (4.2) |
| Unknown | 5 (5.9) | 80 (94.1) | 85 (3.5) |
| Infant PMTCT intervention | | | |
| NVP/CTX/AZT | 60 (2.5) | 2,313 (97.5) | 2,373 (98.7) | \( <0.001 \)^f |
| None | 2 (13.3) | 13 (86.7) | 15 (0.6) |
| Unknown | 6 (35.3) | 11 (64.7) | 17 (0.7) |
| Clinical outcome | | | |
| Alive on HAART | 51 (100.0) | 0 (0.0) | 51 (2.1) | \( <0.001 \)^f |
| Dead | 7 (100.0) | 0 (0.0) | 7 (0.3) |
| Discharged\(^d\) | 0 (0.0) | 2,335 (100.0) | 2,335 (97.1) |
| Lost to follow up | 4 (80.0) | 1 (20.0) | 5 (0.2) |
| Transferred out\(^i\,\(^j\) | 6 (85.7) | 1 (14.3) | 7 (0.3) |

HEI: HIV-exposed infant; ANC: antenatal care; ART: anti-retroviral therapy; ARV: anti-retroviral drugs; CD4: Cluster differentiated cell type 4; NVP: nevirapine; PMTCT: prevention of mother-to-child transmission of HIV; CTX: cotrimoxazole; AZT: azidothymidine; ART: anti-retroviral therapy; DNA: Deoxyribonucleic acid; PCR: Polymerase chain reaction.

\(^*\) Row percentages.

\(^\text{**}\) Column percentages.

\(^a\) As at time of antenatal care booking for pregnancy with study infant, unless otherwise indicated.

\(^b\) Includes single, divorced and widowed women.

\(^c\) Patients’ homes, churches/religious centers and traditional birth attendant centers.

\(^d\) Received during antenatal care or labour.

\(^e\) Earliest DNA PCR test.

\(^f\) Likelihood ratio.

\(^g\) Fisher’s exact.

\(^h\) At antenatal booking for index pregnancy.

\(^i\) From PMTCT program to regular pediatric care.

\(^j\) Formal transfer of care to another facility.

https://doi.org/10.1371/journal.pone.0263921#t002
mixed feeding. Exclusive replacement feeding of HEI perfectly predicted negative HIV status of HEI at 18 months, which was why it was omitted from the model.

Pregnant women living with HIV who did not receive ART antenatally or during labour were nearly 10 times (aOR 9.59, \( p < 0.001 \)) more likely to transmit HIV to their infants compared to women who received chemoprophylaxis.

**Discussion**

In this retrospective cross-sectional study, 68 out of 2,405 (2.8%) HIV-exposed infants tested HIV-positive at final outcome assessment in Nigeria. This is lower than the national estimate of 25% [1], but higher than post-breastfeeding/final outcome rates of 0.7%-1% available from prior Nigerian studies using data collected between 2010 and 2016 in the North-Central [14, 19] and South-East zones [20]. Compared to the 2020 national estimates of 15% and 10% respectively [1], the relatively low early (2.7%) and final (2.8%) MTCT rates in our infant cohort, is encouraging. However, this data is not population-based and as such, may underestimate final outcome MTCT rates. Furthermore, our analysis is based on 2016 final outcomes data, and may not reflect the current situation.

Nonetheless, available data on final outcomes, including population-based data in African countries is scarce. A population-based South African study reported an early (4 to 8-week) postpartum MTCT rate of 3.5% among 10,178 HEI; however, there was no final outcome
A study from Zimbabwe reported an 18-month MTCT final outcome of 0.3% among a nationally-representative sample of 6,051 HEI [22], which was approximately 10 times lower than we found in our Nigerian cohort. However, there is wide variation across the continent; non-population-based studies from other African countries have reported post-breastfeeding/final outcome HIV positivity rates ranging from 2.2% to 9.6% for cohorts with approximately 170 to 3,780 HEI [23–27].

Our final outcome analysis showed that 0.3% (n = 8) of 2,333 HEI with negative six-week DNA PCR tests were ultimately found HIV-positive at or after 18 months of age. HEI who initially test PCR-negative can later become HIV-infected due to late ex utero MTCT (e.g. during breastfeeding or mixed feeding). Also, approximately 10% of previously PCR-positive infants tested negative at final outcome assessment. The initial PCR positive results may have represented false positives due to the presence of proviral HIV DNA or cell associated HIV RNA that increase the sensitivity of EID assays [28]; or cross-contamination of samples in the laboratory, which may be less likely [29].

### Table 3. Multivariate logistic regression analysis for predictors of final HIV outcomes of HIV-exposed infants.

| Variable                                    | Crude OR [95% CI] | p     | Adjusted OR [95% CI] | p     |
|---------------------------------------------|-------------------|-------|----------------------|-------|
| Maternal ART/ARV prophylaxis                |                   |       |                      |       |
| Yes                                         | 1.0 [Ref]         |       | 1.0 [Ref]            |       |
| No                                          | 9.59 [3.15–29.19] | <0.001| 4.76 [1.23–18.42]    | 0.024 |
| Unknown                                     | 5.69 [2.35–9.96]  | <0.001| 8.14 [3.78–17.55]    | <0.001|
| Delivery mode                               |                   |       |                      |       |
| Caesarean section                           | 1.0 [Ref]         |       | 1.0 [Ref]            |       |
| Spontaneous vaginal                         | 2.41 [0.58–9.93]  | 0.224 | 3.23 [0.69–15.15]    | 0.137 |
| Maternal place of delivery                  |                   |       |                      |       |
| Health facility                             | 1.0 [Ref]         |       | 1.0 [Ref]            |       |
| Non-health facility                         | 2.20 [1.10–4.39]  | 0.025 | 1.28 [0.51–3.22]     | 0.597 |
| Unknown                                     | 0.60 [0.08–4.38]  |       | 0.611                | 0.15 [0.02–1.46] | 0.102 |
| Maternal residence                          |                   |       |                      |       |
| Rural                                       | 1.0 [Ref]         |       | 1.0 [Ref]            |       |
| Urban                                       | 0.47 [0.28–0.81]  | 0.006 | 0.45 [0.25–0.81]     | 0.008 |
| Unknown                                     | 1.45 [0.67–3.11]  | 0.343 | 0.29 [0.11–0.79]     | 0.016 |
| Infant feeding practice                     |                   |       |                      |       |
| Mixed feeding                               | 1.0 [Ref]         |       | 1.0 [Ref]            |       |
| Exclusive breast feeding                    | 0.52 [0.30–0.13]  | <0.001| 0.04 [0.02–0.10]     | <0.001|
| Exclusive replacement                       | Omitted           |       |                      |       |
| Missing                                     | 0.16 [0.05–0.50]  | 0.001 | 0.06 [0.02–0.24]     | <0.001|
| Infant birth weight                         |                   |       |                      |       |
| <2.5kg                                      | 1.0 [Ref]         |       | 1.0 [Ref]            |       |
| ≥2.5kg                                      | 0.48 [0.26–0.90]  | 0.022 | 0.40 [0.21–0.80]     | 0.009 |
| Infant PMTCT intervention                   |                   |       |                      |       |
| NVP/CTX/AZT                                 | 1.0 [Ref]         |       | 1.0 [Ref]            |       |
| None                                        | 4.57 [1.31–26.83] | 0.021 | 2.39 [0.43–13.37]    | 0.320 |
| Unknown                                     | 11.02 [7.53–58.73]| <0.001| 8.88 [1.87–42.07]    | 0.006 |

ART: anti-retroviral therapy; ARV: anti-retroviral drugs; NVP: Nevirapine; PMTCT: Prevention of mother-to-child transmission of HIV; CTX: cotrimoxazole; AZT: Azidothymidine.

* Received during antenatal care or labour.

b Patients’ homes, churches/religious centers and traditional birth attendant centers.

https://doi.org/10.1371/journal.pone.0263921.t003
Maternal ART/ARV prophylaxis

In our study, lack of, or unknown receipt of maternal ART, which also served as infant MTCT prophylaxis, was associated with HIV-positive final outcome status among HEI. This is a well-documented phenomenon among both final outcome [19, 22] and early MTCT studies [21, 30]. Prior studies have established that lack of; or inadequate HIV treatment or prophylaxis results in a higher maternal viral load during pregnancy, delivery or breastfeeding [31–33].

The uptake of maternal ART/ARV (antiretrovirals) in our study (91.6%) is higher than the 2020 coverage (44%) for eligible pregnant women in Nigeria’s PMTCT program [1]. This should be interpreted with caution, as our study is not population-based and did not include pregnant women who did not enroll in, or have access to the services and support received in PMTCT programs in the nine included states or across the entire country. Several factors occurring throughout the PMTCT cascade including at the interpersonal, community, healthcare facility and policy/governance levels contribute to low access to maternal ART in Nigeria and other African countries [34–40]. We expect that as lifelong treatment coverage improves in Nigeria, more women living with HIV would have early access, remain adherent and on ART throughout their first and subsequent pregnancies. Also, increasingly accessible point-of-care and birth testing strategies would enable prompt linkage of infants testing HIV-positive to lifesaving ART and minimize missed opportunities for presentation, testing and linkage.

Maternal residence

Pregnant women living with HIV in rural areas were about two times more likely to transmit HIV to their HEIs compared to their urban counterparts, similar to findings in Ethiopia [41]. Another study posited that urban-dwelling women have better knowledge about HIV than their rural counterparts, due in part to less access to education campaigns in poorly-reached areas [42]. Among urban women, easier access to health facilities and skilled healthcare workers contribute to lower rates of HIV positive final outcomes among HEI, due to increased receipt of services like adherence counselling and quality patient-provider engagements; while an underdeveloped transport system, poor telecommunications, drug stock outs, understaffed and over pressured primary health centers, and inadequately trained clinic staff typify the structural barriers to PMTCT in rural areas [43–45].

Infant feeding practice

We reported a higher proportion and increased likelihood of HIV positive final outcomes for HEI who received mixed feeding compared to those on exclusive breastfeeding. Exclusive breastfeeding protects against HIV transmission by protecting the integrity of the mucosa through antibodies and innate factors in breast milk which inhibit the uptake, transport, and replication of HIV-1 [46]. Mixed feeding with infant formula causes non-breast milk antigen-induced inflammation that increases infants’ vulnerability to HIV infection [47]. Compared to mixed feeding, exclusive breastfeeding is less liable to cause breast health issues like subclinical mastitis and breast abscesses which are associated with increased breastmilk viral loads [48]. Ultimately, infants receiving mixed feeding are at as much as 42 times higher risk of acquiring HIV infection compared to those exclusively breastfeeding [41].

Although we did not explore these or similar factors, among mothers living with HIV, lack of formal education [49] lack of pre-existing norms for exclusive breast feeding, financial vulnerability, non-disclosure of HIV status, perception of insufficient breast milk, social and family advice or pressure/influence, and conflicting messages from healthcare workers have been associated with mixed feeding, which increases the risk of MTCT [50].
Infant birthweight

Several studies have established an association between maternal HIV infection and an increased risk of infant low birth weight [51, 52]. In our study, babies with low birth weight of \( \leq 2.5 \) kg had a higher risk of HIV-positive outcomes than those with birth weight \( > 2.5 \) kg, similar to prior findings in Zimbabwe [53]. Although the mechanism of the interaction between maternal HIV and low infant birth weight is still unknown, a speculated cause is HIV infection-induced placental inflammation that disrupts placental functions, including maternal-fetal exchange [54].

Infant PMTCT intervention

Similar to previous studies in Ethiopia and Nigeria [26, 55, 56], infants who did not receive ARV prophylaxis, or for whom this was unknown were more likely to be HIV-positive at 18 months compared to those who received ARV prophylaxis. Infant ARV prophylaxis reduces the risk of MTCT during pregnancy, labour, delivery, and breastfeeding [26].

Factors not associated with MTCT (non-findings)

Although there was no statistical difference in final infant outcomes for mothers who delivered at or outside of health facilities in our study, other studies have reported that delivery in non-health facilities is associated with poor outcomes for infants of pregnant women living with HIV [14, 25, 41], due to lack of skilled birth attendants to ensure safe delivery practices, and the unavailability of PMTCT interventions typically available at health facilities [26]. Several studies have reported that spontaneous vaginal delivery compared with assisted delivery [26] or elective caesarean section compared to vaginal delivery [20, 32] is associated with negative final infant HIV outcomes, which our study was not designed to evaluate.

Limitations

Our study is limited by variables missing/unknown, some of which we are unable to explain. These missing data include two month EID information, as only six week EID data were available for detailed analysis. We did not apply further statistical approaches—e.g. multiple imputation—to address missing data, which can generate misleading results; we found our simpler approach sufficient for our purpose. Furthermore, we were unable to classify DNA PCR result by infant chronological age, due to incomplete records for mother-infant pairs. The HIV status of HEI who did not present for early and/or final testing was not evaluated. Also, HEI presenting later than six weeks for EID and earlier than 18 months for final outcomes were excluded from analysis. This was done to reduce confounding of outcomes assessments related to programmatically-recommended testing time-points for EID and final outcome. It is plausible that the HIV positivity rate would likely have been higher if data from “off-schedule” infant testing were included. The absence of maternal viral load data limits analysis of its role as a predictor of HEI final outcome in this study. Finally, the retrospective collection of data might have been affected by data collection errors.

Strengths of the study

The analysis of a birth cohort of more than 2,400 HEI-maternal pairs across 10 of Nigeria’s 37 states and territories improved the study’s reliability and validity. Furthermore, data was collected from both public and private health facilities across all healthcare delivery levels in both rural and urban settings in the included states, strengthening study generalizability. Finally, the application of multivariate analysis to routinely reported programmatic data addresses
potential cofounders to better reflect real-world outcomes and impact of the PMTCT program.

Conclusions

Our study assessed 18 to 24 month final outcomes for a relatively large cohort of HIV-exposed infants in Nigeria’s PMTCT program. While this analysis was not population based, it provides further insight into downstream impact of maternal-level interventions on infants and highlights factors associated with a final infant HIV positive outcome, essentially a failure of the PMTCT program.

Drawing from our findings, we recommend strengthened programmatic focus on early access to quality antenatal care and maternal ART, especially for women living with HIV in rural areas. Furthermore, we recommend strengthening and sustaining nationwide implementation of education and sensitization on six-months of exclusive infant breastfeeding concurrent with maternal ART. As maternal ART regimens change and coverage improves, timely, population-level data on HEI final outcome is needed to further inform PMTCT policy and implementation.

Acknowledgments

The authors would like to thank all PMTCT program and Strategic Information personnel at the Institute of Human Virology Nigeria (IHVN), as well as PMTCT staff at all health facilities included in this study. We also acknowledge support to IHVN from the United States President’s Emergency Plan for AIDS Relief (PEPFAR) to implement routine HIV services at the included facilities.

Author Contributions

Conceptualization: Bidemi Harry-Erin.
Data curation: Bidemi Harry-Erin, Martha Okposo, Ahmad Aliyu, Nicaise Ndemb.
Formal analysis: Babatunde Adelekan, Bidemi Harry-Erin.
Methodology: Babatunde Adelekan, Bidemi Harry-Erin, Nadia A. Sam-Agudu.
Project administration: Patrick Dakum.
Resources: Patrick Dakum.
Supervision: Martha Okposo, Ahmad Aliyu, Nicaise Ndemb, Patrick Dakum, Nadia A. Sam-
Agudu.
Validation: Babatunde Adelekan, Bidemi Harry-Erin.
Visualization: Babatunde Adelekan, Bidemi Harry-Erin, Martha Okposo, Ahmad Aliyu, Nicaise Ndemb, Nadia A. Sam-Agudu.
Writing – original draft: Babatunde Adelekan, Bidemi Harry-Erin, Nadia A. Sam-Agudu.
Writing – review & editing: Babatunde Adelekan, Bidemi Harry-Erin, Martha Okposo, Ahmad Aliyu, Nicaise Ndemb, Patrick Dakum, Nadia A. Sam-Agudu.

References

1. UNAIDS Data sheet 2021. AIDS info. [Cited 2021 October 5]. https://aidsinfo.unaids.org/#data-details
2. Global AIDs update, 2021: Confronting Inequalities. Lessons for pandemic responses from 40 years of AIDS. [Cited 2021 October 5]. https://www.unaids.org/sites/default/files/media_asset/2021-global-aids-update_en.pdf

3. UNAIDS. On the fast track to an AIDS free generation: The incredible journey of the global plan towards the elimination of new HIV infections among children by 2015 and keeping their mothers alive. 2016;108. [Cited 2021 October 5]. http://www.unaids.org/sites/default/files/media_asset/GLOBALPlan2016_en.pdf.

4. Hamilton E, Bossiyy B, Ditekemena J, Esiru G, Fwamba F, Goga AE, et al. Using the PMTCT cascade to accelerate achievement of the global plan goals. J Acquir Immune Defic Syndr [Internet]. 2017; 75: S27–35. https://doi.org/10.1097/QAI.0000000000001325 PMID: 28398994

5. Ikechebelu JI, Sagay AS, Agboghoroma C. Nigerian prevention of mother to child transmission of human immunodeficiency virus program: The journey so far. Journal of HIV and Human Reproduction. 2013; 1(1):1.

6. UNAIDS. The Global Plan Towards the Elimination of New HIV Infections Among Children by 2015 and Keeping Their Mothers Alive Prepared for the iERG by UNAIDS May 15, 2015 About the Global Plan Key results from 2013. 2015;1–8. [Cited 2021 October 5]. https://www.who.int/woman_child_accountability/ierg/reports/UNAIDS_submission_iERG_2015.pdf

7. Adeyinka DA, Agogo EA, Ozigbu CE, Aboje S, Anyaike C, Asadu EC, et al. Missed opportunities in the prevention of mother-to-child transmission of HIV infection: experience from a national programme in Nigeria. Int J STD AIDS. 2016; 27(14):1338–41. https://doi.org/10.1177/0956462416665027 PMID: 27516454

8. UNAIDS. Start Free Stay Free AIDS Free-2020 Report 2020. [Cited 2021 October 5]. https://www.unaids.org/sites/default/files/media_asset/start-free-stay-free-aids-free-2020progress-report_en.pdf.

9. Sam-Agudu NA, Ramadhani HO, Isha C, Erekaoha S, Fan-Osuala C, Anaba U, et al. The Impact of Structured Mentor Mother Programs on Presentation for Early Infant Diagnosis Testing in Rural North-Central Nigeria: A Prospective Paired Cohort Study. J Acquir Immune Defic Syndr. 2017 Jun 1; 75 Suppl 2:S182–S189. https://doi.org/10.1097/QAI.00000000000001345 PMID: 28498188

10. Pharr JR, Obiefune MC, Ezeanolue CO, Osuji A, Ogidi AG, Gbadamosi S, et al. Linkage to care, early infant diagnosis, and perinatal transmission among infants born to HIV-infected Nigerian mothers: Evidence from the healthy beginning initiative. J Acquir Immune Defic Syndr. 2016; 72(July): S154–60. https://doi.org/10.1097/QAI.0000000000001051 PMID: 27355503

11. Afe AJ, Adewum N, Emokpa A, Fagorala T, Disu AE, Abidoye G, et al. Outcome of PMTCT services and factors affecting vertical transmission of HIV infection in Lagos, Nigeria. HIV AIDS Rev [Internet]. 2011; 10(1):14–8.

12. Aliyu MH, Blevins M, Audet CM, Kalish M, Gehi UI, Onwujekwe O, et al. Integrated prevention of mother-to-child HIV transmission services, antiretroviral therapy initiation, and maternal and infant retention in care in rural North-Central Nigeria: a cluster-randomised controlled trial. The Lancet HIV. 2016; 3(5):e202–11. https://doi.org/10.1016/S2352-3018(16)00018-7 PMID: 27126487

13. Oluyeimi AO, Ilatunya SO, Ogundare EO. PCR Results and PMTCT Treatment Outcomes among HIV-Exposed Infants in a Tertiary Hospital in Nigeria, 2010–2014. Int J MCH AIDS. 2015; 3(2):168–73. PMID: 27621996

14. Sagay A, Ebonyi A, Meloni S, Musa J, Oguche S, Eckwempu C, et al. Mother-to-Child Transmission Outcomes of HIV-Exposed Infants Followed Up in Jos North-Central Nigeria. Curr HIV Res [Internet]. 2015; 13(3):193–200. PMID: 25986370

15. Okafor I, Ugwu E, Obi S, Odugbode T, Virtual elimination of mother-to-child transmission of human immunodeficiency virus in mothers on highly active antiretroviral therapy in Enugu, South-Eastern Nigeria. Ann Med Health Sci Res [Internet]. 2014; 4(4):615. PMID: 25221715

16. IHVN: Our History. [cited 2021 March 3]. http://ihvnigeria.org/about-us/ourhistory/

17. FMOH. Integrated National Guidelines for HIV Prevention Treatment and Care https://www.childrenandaidss.org/sites/default/files/2017-05/Nigeria-Integrated-National-Guidlines-For-HIV-Prevention-treatment-and-care-2014.pdf. Accessed January 11, 2022.

18. PEPFAR Monitoring Evaluation and Reporting Indicator Reference Guide. MER-2.0-Version2.1. https://srfhrindex.srhrfollorl/uploads/2018/11/2017_PEPFAR-Monitoring-Evaluation-and-Reporting-Indicator-Reference-Guide_MER-2.0-Version-2.1.pdf. Accessed January 12, 2022.

19. Oleribe O, Eneneke E, Udofo A, Ekem C, Osita-Oleribe PI, Kim JU, et al. Assessment of the effectiveness of PMTCT program in eight service delivery points in North Central Nigeria. HIV AIDS—Research and Palliative Care. 2018; 10:253–9. https://doi.org/10.2147/HIV.S157685 PMID: 30538583
20. Iloh KK, Iloh ON, Ikefuna AN, Ibeziako NS, Ubesie AC, Emodi IJ. Determinants of mother-to-child transmission of HIV despite PMTCT interventions in Enugu, Nigeria. South African J Child Heal [Internet]. 2007; 9(2):49–52.

21. Goga AE, Dinh T, Jackson DJ, Lombard C, Delaney KP, Puren A, et al. First population-level effectiveness evaluation of a national programme to prevent HIV transmission from mother to child, South Africa. J Epidemiol Community Health. 2015 Mar; 69(3):240–8. https://doi.org/10.1136/jech-2014-204535 PMID: 25371480

22. Dinh T, Mushavi A, Shiraishi RW, Barr BT, Balachandra S, Shambira G, et al. Impact of Timing of Antiretroviral Treatment and Birth Weight on Mother-to-Child Human Immunodeficiency Virus Transmission: Findings from an 18-Month Prospective Cohort of a Nationally Representative Sample of Mother-Infant Pairs During the Transition from Option A to Option B+ in Zimbabwe. Clin Infect Dis 2018 Feb 1; 66(4):576–585. https://doi.org/10.1093/cid/cix820 PMID: 29401270

23. Elyanu, PJ, "Outcomes of HIV exposed infants before and after implementing Option B+ prevention of mother to child HIV transmission guidelines in Mulago Hospital, Uganda: A retrospective cohort study" (2016). Texas Medical Center Dissertations (via ProQuest). AAI10131758. https://digitalcommons.library.tmc.edu/dissertations/AAI10131758

24. Derebe G, Biadgilign S, Trivelli M, Hundessa G, Robi ZD, Gebremiriam M, et al. Determinant and outcome of early diagnosis of HIV infection among HIV-exposed infants in southwest Ethiopia. BMC Research Notes. 2014 May 22; 7(1). https://doi.org/10.1186/1756-0500-7-309 PMID: 24885260

25. Kassaw MW, Abebe AM, Abate BB, Tlaye KG, Kassie AM. Mother-to-child HIV transmission and its associations among exposed infants after Option B+ guidelines implementation in the Amhara regional state referral hospitals, Ethiopia, International Journal of Infectious Diseases. 2020 Jun 1; 95:268–75. https://doi.org/10.1016/j.ijid.2020.03.006 PMID: 32247052

26. Tsehay AK. Factors associated with HIV-positive sero-status among exposed infants attending care at health facilities in Bahir Dar administration, Ethiopia: Evidence from medical records. Cogent Medicine. 2019 Jan 1; 6(1):1623754.

27. Valère M, Nelly K, Mefo N, Pascal F. Mother to Child Transmission of HIV after Option B+ in Low Income Environment. Open Journal of Obstetrics and Gynecology. 2018; 08(12):1163–75.

28. Smit PW, Sollis KA, Fiscus S, Ford N, Vitoria M, Essajee S, et al. Systematic review of the use of dried blood spots for monitoring HIV viral load and for early infant diagnosis. PLoS ONE. 2014; 9(3):1–8. https://doi.org/10.1371/journal.pone.0086461 PMID: 24603442

29. Lofgren SM, Morrissey AB, Chevallier CC, Malabeja AI, Edmonds S, Amos B, et al. NIH Public Access. Evaluation. 2010; 23(May 2009):2459–66.

30. Tiam A, Kassaye SG, Macheke R, Tukei V, Gill MM, Mokone M, et al. Comparison of 6-week PMTCT outcomes for HIV-exposed and HIV-unexposed infants in the era of lifelong ART: Results from an observational prospective cohort study. PLoS ONE. 2019 Dec 1; 14(12). https://doi.org/10.1371/journal.pone.0263921 February 14, 2022

31. Ellington SR, King CC, and Kourtis AP. Host factors that influence mother-to-child transmission of HIV-1: genetics, coinfections, behavior and nutrition. Vol. 6, Future Virology. 2011. p. 1451–69. https://doi.org/10.2217/fvl.11.119 PMID: 29348780

32. Liu JF, Liu G, Li ZG. Factors responsible for mother to child transmission (MTCT) of HIV-1 –a review. European Review for Medical and Pharmacological Sciences 2017; 21 (4 Suppl): 74–78. PMID: 29165760

33. Ngwende S, Gombe NT, Midzi S, Tshimanga M, Shambira G, Chadambuka A. Factors associated with HIV infection among children born to mothers on the prevention of mother to child transmission programme at Chitungwiza Hospital, Zimbabwe, 2008 [Internet]. 2013. http://www.biomedcentral.com/1471-2458/13/1181.

34. Cornelius LJ, Erekahe SC, Okundaye JN, Sam-Agudu NA. A Socio-Ecological Examination of Treatment Access, Uptake and Adherence Issues Encountered by HIV-Positive Women in Rural North-Central Nigeria. Journal of Evidence-Informed Social Work. 2017;1–14.

35. Colvin CJ, Konopka S, Chalker JC, Jonas E, Albertini J, Amzel A, et al. A systematic review of health system barriers and enablers for antiretroviral therapy (ART) for HIV-infected pregnant and postpartum women. PLoS one. 2014; 9(10): e108150–e. https://doi.org/10.1371/journal.pone.0108150 PMID: 25303241

36. Al-Mujtaba M, Cornelius LJ, Galadanci H, Erekahe S, Okundaye JN, Adeyemi OA, et al. Evaluating Religious Influences on the Utilization of Maternal Health Services among Muslim and Christian Women in North-Central Nigeria. Biomed Res Int. 2016. https://doi.org/10.1155/2016/3645415 PMID: 27006944
37. Gourlay A, Birdthistle I, Mburu G, Iorpenda K, Wringe A. Barriers and facilitating factors to the uptake of antiretroviral drugs for prevention of mother-to-child transmission of HIV in sub-Saharan Africa: a systematic review. Journal of the International AIDS Society. 2013; 16(1):1858.

38. Olakunde BO, Adeyinka DA, Olakunde OA, Ozigbu CE, Ndulue CD, Oladele T, et al. Correlates of antiretroviral coverage for prevention of mother-to-child transmission of HIV in sub-Saharan Africa. AIDS care. 2019; 31(10):1255–60. https://doi.org/10.1080/09540121.2019.1587346 PMID: 30829049

39. Erekaha SC, Cornelius LJ, Bessaha ML, Ibrahim A, Adeyemo GD, Fadare M, et al. Exploring the acceptability of Option B plus among HIV-positive Nigerian women engaged and not engaged in the prevention of mother-to-child transmission of HIV cascade: a qualitative study. SAHARA-J: Journal of Social Aspects of HIV/AIDS. 2018; 15(1):128–37. https://doi.org/10.1080/17290376.2018.1527245 PMID: 30253709

40. Adelekan B, Andrew N, Nta I, Gomwalk A, Ndemb N, Mensah C, et al. Social barriers in accessing care by clients who returned to HIV care after transient loss to follow-up. AIDS AIDS Research and Therapy. 2019 Aug 12; 16(1). https://doi.org/10.1186/s12981-019-0231-5 PMID: 31405386

41. Wudineh F, Damtew B. Mother-to-Child Transmission of HIV Infection and Its Determinants among Exposed Infants on Care and Follow-Up in Dire Dawa City, Eastern Ethiopia. AIDS Research and Treatment. 2016; 2016.:1–6. https://doi.org/10.1155/2016/3262746 PMID: 26989507

42. Burgoyne AD, Drummond PD. Knowledge of HIV and AIDS in women in sub-Saharan Africa. Afr J Reprod Health [Internet]. 2008; 12(2):14–31. PMID: 20695040

43. Skinner D, Mfecane S, Gumede T, Henda N, Davids A. Barriers to accessing PMTCT services in a rural area of South Africa. [African Journal of AIDS Research]. 2005 Nov; 4(2):115–23. https://doi.org/10.2989/16085900509430350 PMID: 25870888

44. Hampanda K. Vertical Transmission of HIV in Sub-Saharan Africa: Applying Theoretical Frameworks to Understand Social Barriers to PMTCT. ISRN Infectious Diseases. 2013 Sep 24; 2013:1–5.

45. Anaba U, Sam-Agudu NA, Ramadhani HO, Torbunde N, Abimiku A, Dakum P, et al. Missed Opportunities for Early Infant Diagnosis of HIV in Rural North-Central Nigeria: A Cascade Analysis from the INSPIRE MoMent Study. PLoS One. 2019 Jul 31; 14(7):e0220616. https://doi.org/10.1371/journal.pone.0220616 PMID: 31365571

46. Shen R, Achenbach J, Shen Y, Palaia J, Rahkola JT, Nick HJ, et al. Mother-to-child HIV-1 transmission events are differentially impacted by breast milk and its components from HIV-1 infected women. PLoS ONE. 2015; 10(12):1–16.

47. Smith MM, Khan L. Exclusive breast-feeding: does it have the potential to reduce breast-feeding transmission of HIV-1? Nutr Rev. 2000; 58(11):333–40. https://doi.org/10.1111/j.1753-4887.2000.tb01830.x PMID: 11140904

48. Coovadia HM, Rollins NC, Bland RM, Little K, Couttsoudis A, Bennish ML, et al. Mother-to-child transmission of HIV-1 infection during exclusive breastfeeding in the first 6 months of life: an intervention cohort study. Lancet. 2007; 369(9567):1107–16. https://doi.org/10.1016/S0140-6736(07)60283-9 PMID: 17398310

49. Ickes SB, Hurst TE, Flax VL. Maternal Literacy, Facility Birth, and Education Are Positively Associated with Better Infant and Young Child Feeding Practices and Nutritional Status among Ugandan Children. J Nutr [Internet]. 2015; 145(1):2578–86. https://doi.org/10.3945/jn.114.154346 PMID: 25977782

50. Al-Mujtaba M, Sam-Agudu NA, Khatri R. Barriers to the practice of exclusive breastfeeding among HIV-positive mothers in sub-Saharan Africa: A scoping review of counselling, socioeconomic and cultural factors. Journal of AIDS and HIV Research. 2016; 8(6):70–79.

51. Xiao PL, Zhou YB, Chen Y, Song XX, Shi Y, et al. Association between maternal HIV infection and low birth weight and prematurity: A meta-analysis of cohort studies. BMC Pregnancy and Childbirth. 2015 Oct 8; 15(1). https://doi.org/10.1186/s12884-015-0684-z PMID: 26450802

52. Larrey A, Marquis GS, Mazur R, Perez-escamilla R, Ampofo W, Sellen D, et al. Maternal HIV is associated with reduced growth in the first year of life among infants in the Eastern region of Ghana: The Research to Improve Infant Nutrition and Growth (RiING) Project. Matern Child Nutr. 2015; 10 (4):604–16.

53. Gumbo FZ, Duri K, Kandawasvika GQ, Kurewa NE, Mapingure MP, Munjomwa MW, et al. Risk factors of vertical transmission in a cohort of women under a PMTCT program at three periurban clinics in a resource-poor setting. J Perinatol [Internet]. 2010; 30(11):717–23. Available from: https://doi.org/10.1038/jp.2010.31 PMID: 20336078

54. Ackerman W and Kwiek JJ. Role of the Placenta in Adverse Perinatal Outcomes Among HIV-1 Seropositive Women. J Nippon Med Sch. 2013; 80(2):90–94. https://doi.org/10.1272/jnma.80.90 PMID: 23657060
55. Berhan Z, Abebe F, Gedefaw M, Tesfa M, Assefa M, Tafere Y. Risk of HIV and associated factors among infants born to HIV positive women in Amhara region, Ethiopia: a facility based retrospective study. BMC Res Notes. 2014; 7(1):876. https://doi.org/10.1186/1756-0500-7-876 PMID: 25475398

56. Anoje C, Aiyenigba B, Suzuki C, Badru T, Akpoigbe K, Odo M, et al. Reducing mother-to-child transmission of HIV: Findings from an early infant diagnosis program in south-south region of Nigeria. BMC Public Health [Internet]. 2012; 12(1):184. https://doi.org/10.1186/1471-2458-12-184 PMID: 22410161